Resverlogix Corp. (RVXCF) 是一家上市公司 属于 医疗保健 板块，经营于 生物科技 行业. 公司总部位于 Calgary, AB, 加拿大. 现任CEO为 Donald J. McCaffrey.
RVXCF 拥有 IPO日期为 2009-02-13, 19 名全职员工, 在 Other OTC, 市值为 $24.6M.
Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for disease states with high unmet medical needs. It is developing apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor that is in Phase III clinical trial for patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease, and neurodegenerative diseases. Resverlogix Corp. has a partnership with Eversana Life Science Services, LLC to support the pending launch of the commercialization of apabetalone for Covid-19 in the United States and Canada. The company is headquartered in Calgary, Canada.
